by Hugoline G. de Haan, Irene D. Bezemer, Carine J. M

Slides:

Advertisements

Similar presentations

Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men by Bas de Laat, Philip G. de Groot, Ronald H.

Advertisements

Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype by Gabriele Migliorini, Bettina Fiege, Fay.

Arterioscler Thromb Vasc Biol

Central venous line–related thrombosis in children: association with central venous line location and insertion technique by Christoph Male, Peter Chait,

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis by Samantha C. Gouw, H. Marijke.

MBL: mostly benign lymphocytes, but…

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.

Finding a diamond in the (mouse is) rough

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology by Mary Cushman,

One giant leap for pediatric AMKL

Chemokine and Chemokine Receptor Gene Variants and Risk of Non-Hodgkin’s Lymphoma in Human Immunodeficiency Virus-1–Infected Individuals by Charles S.

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping by David C. Johnson, Sophie Corthals,

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.

Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk.

by Jon E. Arnason, Federico Campigotto, Donna Neuberg, and James B

Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma by Angela Dispenzieri,

Dots 5 × TABLES MULTIPLICATION.

Dots 5 × TABLES MULTIPLICATION.

Dots 2 × TABLES MULTIPLICATION.

Subjective versus statistical model assessment of mortality risk in open heart surgical procedures Joan M.V Pons, MD, Josep M Borras, MD, Josep A Espinas,

Triplex High-Resolution Melting Assay for the Simultaneous Assessment of IFNL3 rs , ABCB11 rs , and RNF7 rs Genotypes in Chronic.

Dots 3 × TABLES MULTIPLICATION.

Gene-Expression Variation Within and Among Human Populations

Arpita Ghosh, Fei Zou, Fred A. Wright

Dots 6 × TABLES MULTIPLICATION.

A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms by Carolina Martínez-Laperche, Elena.

Dots 2 × TABLES MULTIPLICATION.

Dots 4 × TABLES MULTIPLICATION.

Jon Wakefield The American Journal of Human Genetics

Serum LAMC2 levels in pancreatic adenocarcinoma (PDAC) and other samples from Japan. Serum LAMC2 levels in pancreatic adenocarcinoma (PDAC) and other samples.

A and B, ROC curves of the proteomics panel diagnosis.

Pritam Chanda, Aidong Zhang, Daniel Brazeau, Lara Sucheston, Jo L

Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.

Laura M. Dember, Erika F. Holmberg, James S. Kaufman

The Power of Genomic Control

Receiver under the operator characteristic (ROC) curve for the test accuracy of the final risk score in the entire external validation sample (c statistic=0.84,

Comparative receiver operating characteristic (ROC) curves and the area under the curve (AUC) in association with 30-day mortality for severity scores.

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure by Justine E. Marum, David T. Yeung,

Box plots showing the relative difference in distribution of mtDNA copy number per cell between patients with ESRD and healthy control subjects frequency.

(A) ROC for the prediction of 5-year mortality in unoperated significant MR. AUCs and corresponding p values are shown for lateral annulus E/E′ (AUC=0.69,

Receiver operating characteristic (ROC) curves (area under the curve (AUC) (95% CI)) for FACED (forced expiratory volume in 1 s, age, chronic colonisation.

by Wendy Lim, Sara K. Vesely, and James N. George

—ROC curves for each simple test compared with NCS (gold standard) plotting the sensitivity versus 1-specificity (the false-positive rate) for different.

Receiver-operating characteristic curves showing the performance of the diabetes risk score in predicting diabetes in the United Arab Emirates (UAE) citizens.

Fig. 2. Bacterial/viral score in COCONUT-conormalized whole-blood validation data sets. Bacterial/viral score in COCONUT-conormalized whole-blood validation.

Tuning width distributions.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Diagnostic methods 2: receiver operating characteristic (ROC) curves

Diagnostic plots of the TGI PKPD model fitted to the A677 TGI data.

ROC curves for cardiovascular events, all-cause mortality, and disease progression. ROC curves for cardiovascular events, all-cause mortality, and disease.

Dots 3 × TABLES MULTIPLICATION.

Rituximab immunotherapy: it’s getting personal

Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S by Michael Makris, Michael Leach,

CR-rate ratios with 95% CIs

Gary L Grunkemeier, PhD, Ruyun Jin, MD The Annals of Thoracic Surgery

ROC curves showing the performance of the Diabetes Risk Score in predicting diabetes in the 1987 and 1992 cohorts; follow-up of both cohorts continued.

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

Jung-Ying Tzeng, Daowen Zhang The American Journal of Human Genetics

ROC analysis of MIC-1 and CA19-9.

External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation by Roni Shouval, Joshua A. Fein,

Cumulative prevalence of venous thromboembolic events in ITP patients who underwent splenectomy compared with those who did not. Cumulative prevalence.

Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease by Paula Rodriguez-Otero,

Receiver operating characteristic (ROC) curves for discriminating diabetic subjects without retinopathy from control subjects using a logistic regression.

Receiver operator characteristic (ROC) curve for fasting blood glucose (FBG) predicting posttransplantation diabetes (PTD) using time 0 FBG (a) and screening.

Presentation transcript:

Multiple SNP testing improves risk prediction of first venous thrombosis by Hugoline G. de Haan, Irene D. Bezemer, Carine J. M. Doggen, Saskia Le Cessie, Pieter H. Reitsma, Andre R. Arellano, Carmen H. Tong, James J. Devlin, Lance A. Bare, Frits R. Rosendaal, and Carla Y. Vossen Blood Volume 120(3):656-663 July 19, 2012 ©2012 by American Society of Hematology

The 31-SNP risk allele distribution in patients with venous thrombosis and control subjects and corresponding ORs. The number of risk alleles was counted for cases and control subjects (top panel). The 31-SNP risk allele distribution in patients with venous thrombosis and control subjects and corresponding ORs. The number of risk alleles was counted for cases and control subjects (top panel). ORs (95% CI) for venous thrombosis were calculated relative to the median number of risk alleles among control subjects (24 risk alleles; bottom panel). Persons with 15 or less and 36 or more risk alleles were combined for the calculation of the OR because of the low numbers of persons with that few or many risk alleles (bottom panel). Hugoline G. de Haan et al. Blood 2012;120:656-663 ©2012 by American Society of Hematology

Area under the ROC of genetic risk scores based on increasing numbers of SNPs. SNPs were added in order of the OR as found in the literature, starting with rs6025 in the score based on 1 SNP, and ending with CPB2 included in the score of 31 SNPs (Table 1). Area under the ROC of genetic risk scores based on increasing numbers of SNPs. SNPs were added in order of the OR as found in the literature, starting with rs6025 in the score based on 1 SNP, and ending with CPB2 included in the score of 31 SNPs (Table 1). Hugoline G. de Haan et al. Blood 2012;120:656-663 ©2012 by American Society of Hematology

The 5-SNP risk allele distribution in patients with venous thrombosis and control subjects and corresponding ORs. The number of risk alleles was counted for cases and control subjects (top panel). The 5-SNP risk allele distribution in patients with venous thrombosis and control subjects and corresponding ORs. The number of risk alleles was counted for cases and control subjects (top panel). ORs (95% CI) for venous thrombosis were calculated relative to the median number of risk alleles among control subjects (score 2; bottom panel). Persons with 6 or more risk alleles were combined for the calculation of the OR because of the low numbers of persons with that few or many risk alleles (bottom panel). Hugoline G. de Haan et al. Blood 2012;120:656-663 ©2012 by American Society of Hematology

ROC (AUC) curves of the weighted 5-SNP risk score (light gray line), the nongenetic risk score (dotted gray line), and the combined risk score (black line). ROC (AUC) curves of the weighted 5-SNP risk score (light gray line), the nongenetic risk score (dotted gray line), and the combined risk score (black line). The striped black line represents the reference line (no discrimination). Hugoline G. de Haan et al. Blood 2012;120:656-663 ©2012 by American Society of Hematology